Current Meeting     Our Mission     Future & Past Programs      Sponsorship     Board of Directors     Contact Us
Meeting Announcement
Date: Wednesday, April 25th, 2018
Topic: "SYK or Not Sick: Tackling Auto-Immune Diseases with an Oral Spleen Tyrosine Kinase (SYK) Inhibitor"
Speaker: Anne-Marie Duliege, M.D.
Executive Vice President and Chief Medical Officer

The Holiday Inn
275 S Airport Blvd
South San Francisco, CA 94080
650-873-3550 | Map
Next door to the SSF Conference Center
Directions at


$50 before 9PM, Monday, April 23rd
$60 on-site
$40 full-time students pre-registration
$50 full-time students on-site
$3 service fee will be added to the pre-registration price

6:00 PM - networking
7:00 PM - dinner
8:00 PM - presentation

Gold Sponsors

Fisher Clinical
ReImagine Science

Silver Sponsors


Location Sponsor



Spleen tyrosine kinase (SYK) is an important modulator of immune system signaling in B-cells, mast cells, neutrophils, macrophages, natural killer cells, dendritic cells and other cells bearing Fc[gamma]-activating receptors. These cells play a critical role in the inflammatory process by releasing cytokines and other intermediaries. Consequently, SYK represents an intriguing therapeutic target for inflammatory and auto-immune diseases and conditions related to Fc signaling or immune complex-based activation.

Fostamatinib is a potent, selective inhibitor of SYK in development at Rigel Pharmaceuticals. Fostamatinib has shown therapeutic activity during clinical studies of rheumatoid arthritis and non-Hodgkin lymphomas, and is now evaluated in diseases in which the immune system attacks and destroys the body's own red blood cells or blood platelets, such as auto-immune hemolytic anemia and immune thrombocytopenia (ITP). Fostamatinibís NDA for the treatment of adult chronic ITP is currently under FDA review with a PDUFA date of April 17, 2018 (so standby).

Dr. Duliege will review the development of Fostamatinib as a therapeutic agent with a new mechanism of action for these rare, serious diseases with significant unmet need.


Anne-Marie Duliege, M.D., M.S. is a leader with more than 25 years of experience in the biopharmaceutical industry. Since 2016, she has served as Rigel's Executive Vice President and Chief Medical Officer, where she is steering the exploration of SYK inhibition in various disease states. Prior to joining Rigel, Dr. Duliege was a senior advisor and executive consultant in several companies in the Bay Area. From 2004 to 2013, Dr. Duliege was at Affymax Inc., initially as Vice President and then as Chief Medical Officer. Before Affymax, Dr. Duliege worked at Chiron and at Genentech.

Dr. Duliege received her Doctorate of Medicine, her certification in Pediatrics, and an M.S. in Biostatistics from Paris Medical School, and an M.S. in Epidemiology from the Harvard School of Public Health. She is an Adjunct Clinical Assistant Professor at Stanfordís School of Medicine and the Lucile Packard Childrenís Hospital. She also serves on the board of the CIRM, the California Institute for Regenerative Medicine, and as the Chairperson of the board of a nonprofit organization focusing on public health in Africa.

Registration Policy    Registration via CEvent     Map